Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colace Plus is a dual-action over-the-counter (OTC) laxative and stool softener combination product containing docusate sodium (50 mg) and sennosides (8.6 mg). It is indicated for the gentle, overnight relief of occasional constipation. Docusate sodium acts as an anionic surfactant (stool softener) that lowers the surface tension of fecal material, allowing water and lipids to penetrate and soften the stool. Sennosides, derived from the senna plant, are prodrugs that are metabolized by colonic bacteria into the active metabolite rheinanthrone. Rheinanthrone stimulates colonic peristalsis and increases fecal water content by decreasing aquaporin-3 expression and promoting electrolyte secretion. Colace Plus is marketed in Canada by Norwell Consumer Healthcare.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docusate sodium + sennosides.